Objective. To compare the European League Against Rheumatism (EULAR) recommendations for the management of NPSLE with usual care in two tertiary centres and to detect potential pitfalls in their use for diagnosis and treatment.
Introduction
Patients with SLE may experience a variety of neurological and psychiatric manifestations, collectively named NPSLE, that account for significant morbidity and mortality [1] . The prevalence of NPSLE varies widely, from 21% to 95% in various cohorts [2, 3] , in part due to the heterogeneity of manifestations and definitions used [4] . In NPSLE, attribution of neuropsychiatric events to lupus warrants a thorough investigation and exclusion of alternative causes. Indeed, primary NPSLE (events directly attributed to the disease) constitutes <40% of all cases [5, 6] . The remaining cases may be caused by complications of the disease or its therapy (secondary NPSLE), or may be unrelated to SLE and be due to infections, metabolic abnormalities and adverse drug reactions. In primary NPSLE, direct neuronal injury due to autoantibodies against N-methyl-D-aspartate glutamate receptor (anti-NR2), accelerated atherosclerosis and thrombotic diathesis caused by the presence of aPL are considered potential pathogenic mechanisms [7] .
Notwithstanding the significant advances in our understanding of its pathogenesis, NPSLE continues to pose considerable diagnostic and therapeutic challenges. Diagnostic workup and treatment decisions are typically performed on a patient-by-patient basis and often necessitate the involvement of multiple medical specialties. In an effort to homogenize the management of patients with NPSLE, a European League Agaisnst Rheumatism (EULAR) task force has issued a set of recommendations, addressing diagnostic and therapeutic issues using a combination of evidence-based approach and expert consensus [8] . The recommendations cover both general NPSLE and specific NPSLE disorders, identify risk factors for its occurrence, and provide evidence on the value of diagnostic modalities and therapeutic options. In view of the former considerations, we sought to compare the EULAR recommendations against usual clinical care of NPSLE patients in two tertiary hospital centres, in an attempt to detect potential limitations in their use for diagnosis and therapy.
Patients and methods

Study population
Two national tertiary referral centres for patients with SLE and suspected neuropsychiatric involvement, Heraklion (Greece) and Cluj (Romania) participated in the study. She study was approved by the Institutional Review Board of the University Hospital of Heraklion (Greece) and that of the Iuliu Hatieganu University of Medicine and Pharmacy in Cluj (Romania). A consent form was not obtained because of the retrospective, observational nature of the study. Patients with confirmed neuropsychiatric involvement were selected (by retrospective chart review) from 650 lupus cases over the last decade (200112) . All patients fulfilled at least four of the revised ACR classification criteria for SLE [9] at the time of NPSLE diagnosis and had undergone regular follow-up in each centre.
For each neuropsychiatric manifestation included in our study, we recorded all diagnostic procedures undergone by the patients, together with the therapies they received. The following variables were also documented: age, gender, ethnicity, smoking and cardiovascular risk factors, disease duration, presence of aPL, history of previous major organ involvement, and medication history. Disease activity and damage at the time of neuropsychiatric event were cross-sectionally assessed with the Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA)-SLEDAI [10] and the SLICC/ACR Damage Index, respectively [11] . Time lag between diagnosis of SLE and occurrence of NPSLE was calculated in years.
The presence of generalized disease activity at the time of the neuropsychiatric event was defined as follows. First, a SELENA-SLEDAI 54 after exclusion of the neuropsychiatric components (non-neuropsychiatric SELENA-SLEDAI). Although not a formally validated index for disease activity, we used the non-neuropsychiatric SELENA-SLEDAI to capture extra-neuropsychiatric disease activity. The cut-off value of 54 was chosen based on data showing that total SLEDAI (SLEDAI-2 K version) scores above 3 or 4 may be more appropriate for defining active disease associated with intensification of immunosuppressive therapy [12] . Second, in the case of nonneuropsychiatric SELENA-SLEDAI <4, if the physician global assessment of disease status (as incorporated in the SELENA-SLEDAI form) was 52, this was indicative of at least medium disease activity [10] . This cut-off value of physician global assessment has been used in previous observational studies to denote severe disease in SLE [13] .
Neuropsychiatric events, work-up and outcome Neuropsychiatric events were defined according to the ACR nomenclature and case definitions [14] . For patients experiencing more than one neuropsychiatric event, each event was registered individually. The attribution of neuropsychiatric syndromes to SLE was based on physician judgement and was made by the treating physician with the help of experts from different disciplines including: internal medicine, infectious diseases, neurology, psychiatry, and neuroimaging. Attribution to SLE was reached following fulfilment of the following criteria: diagnosis of SLE (ACR criteria); presence of neuropsychiatric manifestation included in the ACR nomenclature for NPSLE; absence of another diagnosis that could potentially explain symptoms, according to exclusion and association factors of the ACR nomenclature [14] . Alternative diagnoses included, but were not limited to: CNS infections, metabolic abnormalities, and adverse drug reactions. Following their exclusion, only events directly attributed to lupus were included in the study.
The standard neuroimaging procedure for NPSLE in both centres is the EULAR-recommended brain/spinal cord MRI protocol, which includes conventional MRI www.rheumatology.oxfordjournals.org sequences (T1/T2, FLAIR), diffusion-weighted imaging (DWI) and gadolinium-enhanced T1 sequence. Brain MRIs were interpreted by confirmed neuroradiologists in each centre (both referral centres for NPSLE) as part of the standard approach to diagnosing possible NPSLE. Abnormalities (including white and grey matter hyperintensities, cerebral infarcts, intracranial haemorrhages, cerebral venous thromboses and brain atrophy) were recorded. MRI results were classified as either diagnosis specific when findings were diagnostic of a specific neuropsychiatric entity, or diagnosis non-specific (useful for exclusion of other causes in all other cases). Due to the heterogeneity of manifestations, the outcome of neuropsychiatric events at 6 months was evaluated according to an arbitrary 3-level categorical outcome as improved, stable or worse.
Comparison of clinical care with the EULAR statements and recommendations
The EULAR recommendations comprise a total of 27 statements addressing both the general approach to NPSLE and individual neuropsychiatric syndromes [8] . To calculate concordance rates between clinical practice and the recommendations, we extracted these 27 statements and scrutinized the manuscript text for additional recommendations not included in the statements. Next, we compared the diagnostic and therapeutic decisions applied in each registered neuropsychiatric event against the EULAR recommendations (both the general ones and those specific to the event). In calculation of concordance rates we excluded cases of lupus headache, autonomic disorder, and anxiety disorder (18 cases total; all defined according to ACR case definitions [14] ), since the optimal work-up and treatment for these manifestations is not discussed in the recommendations.
Since the EULAR recommendations were published in 2010, our study period largely reflected usual care prior to their publication. To assess their potential impact on the management of NPSLE, we performed a post hoc analysis to compare agreement between usual care and recommendations relative to the time of NPSLE occurrence (prior to vs after 2010).
Statistical analysis
Data analysis was performed with IBM SPSS Statistics (version 21.0). Descriptive statistics were undertaken for continuous variables, and median values with interquartile ranges (IQR) were calculated. Chi-squared or Fisher's exact test was used to compare categorical variables, and the non-parametric MannWhitney U-test was used to compare continuous variables. Statistical significance was indicated by a two-sided P < 0.05.
Results
Patients and neuropsychiatric events
We identified 94 patients who had experienced a total of 123 lupus-related neuropsychiatric events (n = 71 patients with a single event, n = 17 with two events, n = 6 with three events) ( Table 1) . At the time of the neuropsychiatric event, at least one of the EULAR-defined risk factors for primary NPSLE (previous NPSLE, generalized disease activity, and aPL positivity) was present in almost 80% of events. Approximately 35% of events occurred within the first year after SLE diagnosis (26% as presenting manifestation of the disease).
Neuropsychiatric events and accompanying clinical characteristics (aPL status, SLE activity, and damage at the time of NPSLE occurrence) are listed in supplementary  Table S1 , available at Rheumatology Online. The most prevalent events were cerebrovascular disease (CVD) (n = 21, 17.1%), cognitive dysfunction (n = 18, 14.6%), intractable lupus headache and mood disorder (n = 12 each, 9.8%), seizure disorder and transverse myelitis (n = 11 each, 8.9%). Manifestations (excluding those with fewer than five registered cases) accompanied by the highest generalized (non-neuropsychiatric) disease activity were psychosis and cognitive disorder, followed by myelopathy and CVD.
Brain MRI was performed in 75 neuropsychiatric events (61.0% of total events). In 21 of them (28.0%), MRI was considered normal; in the remaining cases, the most common finding was non-specific periventricular white matter hyperintensities (WMHIs, 40.8% of events), followed by cerebral infarcts (21.1%). Other diagnostic procedures included cerebrospinal fluid (CSF) analysis in 25 events, nerve conduction studies (NCS) in 14, and electroencephalogram in 8 events.
Treatment of NPSLE included steroids (either initiation or escalation of previous dose) in 89 events (72.4%), and immunosuppressants in 73 events (59.3%). The latter included i.v. CYC (42 cases), AZA (22 cases) and rituximab (5 cases). Antithrombotic therapy was administered in 41 neuropsychiatric events (anti-platelet agents in 30 and vitamin K antagonists in 11 cases), most commonly in ischaemic CVD (supplementary Table S2 , available at Rheumatology Online).
In the majority of cases, the short-term outcome of NPSLE was favourable, with 96 events (78%) showing at least mild improvement and 22 (17.9%) remaining stable at 6 months. Manifestations with the most favourable course were psychosis, seizure disorder (the majority having resolved within 6 months) and transverse myelopathy (supplementary Table S2 , available at Rheumatology Online).
Comparison of routine care with the EULAR recommendations
In Table 2 we compare the EULAR recommendations (diagnosis and therapy) with the clinical care followed in the registered NPSLE cases. No statistically significant differences were observed between the two study centres. In addition, we did not observe statistically significant differences (in terms of agreement with the EULAR recommendations) when neuropsychiatric events were stratified according to the time they occurred (prior to or after 2010, year of publication of the EULAR recommendations) (Table 3) .
Diagnostic work-up
The EULAR recommendations advocate the use of brain MRI in CVD, seizures, chorea, and acute confusional state (ACS), and also in selected cases of cognitive dysfunction, myelopathy and psychosis (supplementary Table S3 , available at Rheumatology Online). Brain imaging was performed in 54 of 74 (73.0%) events in which it was recommended, as compared with 21 of 49 (42.9%) events in which it was not recommended (P = 0.01). Notably, in the latter cases brain MRI was more likely to reveal no abnormalities [11/21 (52.4%) vs 10/54 (18.5%), considered normal P = 0.008]. MRI was considered specific for diagnosis only in cases of CVD and also in two cases of cranial neuropathy (V and VII, one each). In all other cases, MRIs were considered non-specific or useful for exclusion of other causes (infections, etc.) for the neuropsychiatric syndrome (supplementary Table S2 , available at Rheumatology Online). The presence of nonspecific WMHIs spanned the whole spectrum of neuropsychiatric events, irrespective of the indication for MRI (P = 0.80).
CSF analysis is specifically recommended by EULAR in cases of ACS, aseptic meningitis, myelopathy and inflammatory demyelinating polyradiculopathy, and it was carried out in 11 of 15 (73.3%) such events. However, lumbar puncture was also performed in cases without clear recommendation, albeit less frequently [14/96 (14.6%) events, P < 0.001]. These were cases of cranial neuropathy, psychosis, mood disorder and cognitive disorder. On all occasions, CSF analysis was performed to exclude alternative diagnoses, particularly infection; findings were suggestive of NPSLE, albeit non-specific in all cases (pleocytosis and/or increased protein), with the exception of a single case of acute demyelinating polyradiculopathy, in which results were typical (elevated protein with the absence of pleocytosis).
Electroencephalogram and NCS were generally undertaken in accordance with the recommendations [8/11 cases of seizures and 8/8 of peripheral neuropathy, respectively). NCS were also performed in more than half of myelopathy cases (6/11) to exclude alternative diagnoses, although this is not explicitly recommended.
Only 27.8% of patients (5/18) with cognitive dysfunction underwent the formal neuropsychological assessment recommended by EULAR [either the 1-h ACR battery or the computer-based automated neuropsychological assessment metrics (ANAM) system], due to lack of availability of neuropsychologists or time constraints. In the remaining cases, diagnosis was made with the Montreal Cognitive Assessment tool (MoCA), a one-page, performance-based questionnaire developed to identify cognitive impairment [15] , and was attributed to SLE after the exclusion of alternative causes [median (IQR) MoCA score 20.0 (6.5), indicative of moderate dysfunction).
Therapy
In accordance with the EULAR recommendations, immunosuppressants were administered more frequently in manifestations felt to reflect an immune/inflammatory process, namely ACS, aseptic meningitis, myelitis and cranial and peripheral neuropathies and psychosis (80.5% vs 47.6% in non-inflammatory events, P < 0.001). Likewise, anti-platelet or anti-coagulation therapies were instituted for events occurring in the presence of aPLs and are thought to be related to the latter, particularly ischaemic CVD, but also chorea, ischaemic optic neuropathy and myelopathy refractory to immunosuppression (75% vs 28.8% in events not considered to be related to aPLs, P = 0.002) ( Table 2) . Regarding CVD in particular, anti-platelet or anti-coagulation was instituted in all 21 cases, with anti-coagulation being reserved for patients fulfilling criteria for APS (7/11 of such cases received vitamin K antagonists). Interestingly, in more than half of CVD events (11/21, 52.4%), physician judgement advocated for the adjunctive use of immunosuppressive treatment; seven patients were treated with CYC, four with AZA and one patient was treated sequentially with AZA, CYC and finally rituximab due to ongoing disease activity and the severity of CVD. To further explore this finding, we assessed levels of disease activity at the time of stroke. A total of 13 of 21 (61.9%) CVD events occurred in the presence of generalized disease activity, and immunosuppressive therapy was instituted in 9/13 (69.2%); major drivers of disease activity were mucocutaneous manifestations (8/13 events), arthritis (7/13), cytopenias (4/13), nephritis (3/13) and serological abnormalities (high anti-dsDNA titre and/ or low serum C3/C4) (6/13 events). No significant differences were found regarding patient age and presence of traditional cardiovascular risk factors (smoking, diabetes, hypertension, dyslipidaemia) between CVD events occurring in the presence or the absence of generalized disease activity (data not shown). The remaining two cases treated with immunosuppressants had lowlevel or no extra-CNS disease activity but suffered from CVD recurrence despite prior antithrombotic treatment. Median [interquartile range (IQR)] non-neuropsychiatric SLEDAI at the time of stroke was significantly higher in cases that received immunosuppression compared with those that did not [6.0 (7.0) vs 2.0 (4.0), respectively, P = 0.04]. All patients (11/11, 100%) who received combined immunosuppression/antithrombotic treatment, and 8/9 (88.9%) of those who received antithrombotic treatment alone had a favourable outcome at 6 months (P = 0.30). In the two cases treated with immunosuppression due to CVD recurrence, no new recurrence was observed at 6 months.
Similarly to diagnosis, the management of SLE patients with cognitive dysfunction was also not in accordance with the EULAR recommendations. Thus, none of the patients underwent psycho-educational interventions (cognitive rehabilitation), and the management of concomitant anxiety and depression was only rarely addressed (Table 2) . Nonetheless, at 6 months, outcome of cognitive dysfunction was mostly stable (supplementary Table S2 , available at Rheumatology Online).
Discussion
In view of the paucity of high-level evidence, diagnostic and therapeutic decisions in NPSLE are based largely on physician judgement. The EULAR recommendations combined existing evidence and expert consensus, in an effort to facilitate management of NPSLE, especially in places that lack adequate expertise. Nevertheless, guidelines carry the inherent problem of being unable to capture all aspects of clinical practice at all times. To this end, we attempted to juxtapose real-life management of SLE www.rheumatology.oxfordjournals.org patients with neuropsychiatric manifestations in two experienced centres with the EULAR recommendations, and to identify areas that may require additional attention.
Notably, the period of our study predominantly included events that occurred before the publication of the EULAR recommendations in 2010. In this regard, the overall good concordance rates between usual care and the recommendations (and the absence of a significant difference in this concordance between events occurring prior to and after publication of the recommendations) is a reassuring observation, as the management of NPSLE has traditionally been based on expert opinion. Moreover, the outcome of NPSLE patients was generally favourable, in accordance with previous reports [16] .
A number of interesting observations were made through the comparison of the EULAR recommendations with routine clinical practice in NPSLE patients. First, brain MRI was performed in excess as part of the diagnostic work-up; in cases where its use is not recommended by EULAR, it often failed to reveal any abnormalities and was not useful for diagnosis and management. Neuroimaging with MRI is considered a sine qua non in the diagnostic work-up of NPSLE. Despite general agreement about its utility, lack of specificity of conventional MRI remains an issue. Indeed, the percentage of normal brain imaging in our cohort was substantial (28%), albeit smaller than reported in other recent studies (4258%) [17, 18] . Specific MRI lesions were present only in cases of CVD and in isolated cases of cranial neuropathy. The most frequent non-specific abnormal MRI finding, periventricular and brainstem WMHIs, was present across all types of manifestation, focal or diffuse, central or peripheral. WMHIs are insufficient to guide therapeutic decisions, as they are also present in SLE patients without neuropsychiatric manifestations and healthy middle-aged individuals [1921] . However, their presence could imply ongoing small vessel disease in SLE, and their incidental detection in lupus patients may dictate aggressive control of traditional cardiovascular risk factors, including hypertension and hypercholesterolaemia. In this regard, an MRI with white matter pathology, although not specific for diagnosis, can be considered useful in some instances. Conventional MRI will thus remain the procedure of choice for NPSLE, especially for the exclusion of alternative diagnoses. However, as NPSLE is not a uniform entity, application of brain MRI should not follow a one size fits all approach.
An important finding of our study was that 62% of CVD cases occurred in the presence of generalized disease activity, and immunosuppressive therapy (including CYC) was given to most of these patients. Optimal management of stroke in the context of active lupus represents a challenge. Acute CVD management should follow the recommendations for the general population, after consultation with a stroke specialist [22] . Secondary prevention includes anti-platelets or anti-coagulation in cases of aPL-associated thrombotic CVD. However, occurrence of non-embolic CVD in a patient with active/flaring SLE could raise the possibility of a concurrent inflammatory component in the atherothrombotic process. SLE per se is considered an independent risk factor for accelerated cardiovascular disease [23] , and a recent study showed increased endothelial dysfunction in active SLE, which was reversed after immunosuppressive therapy [24] . Thus, in clinical practice, and especially in the absence of aPL positivity or pathognomonic MRI findings, the inflammatory and thrombotic/ischaemic states in NPSLE are not always possible to differentiate, or they may coexist. To this end, immunosuppressive therapies, along with anti-platelets/anti-coagulation, could be considered to reduce the disease inflammatory burden and its proatherothrombotic effects. Our short-term data and unpublished experience with longer follow-up of these patients suggest good outcomes with minimal rates of CVD recurrence. Nevertheless, prospective studies are needed to define the natural history of CVD in the context of SLE, in case antithrombotic therapy is or is not combined with immunosuppression.
A major source of discordance between the EULAR recommendations and routine clinical practice concerned the diagnosis and management of cognitive dysfunction in SLE patients. Although this represents one of the most frequent neuropsychiatric manifestations (up to 80% in some cohorts [25] ), the majority of cases have only subtle or mild cognitive deficits that tend to follow a benign course, and only a minority (35%) will develop severe cognitive impairment [26, 27] . Although EULAR recommends the ACR 1-h formal battery of neuropsychological tests or the computer-based ANAM for the assessment of cognitive function in patients with SLE, both modalities are time-consuming and require special training, which limits their widespread use in routine clinical practice. Recent studies have attempted to validate simpler screening tools as more convenient and suitable for routine care. While the Cognitive Symptom Inventory questionnaire failed to show association with the ANAM [28] , application of the MoCA questionnaire in a small study showed good correlation with ANAM scores, with a sensitivity of 83% [29] . We believe it is reasonable that a simple tool such as the MoCA, due to its user-friendly nature and ease of application, may serve for screening of cognition defects in everyday clinical care. Patients with possible cognitive deficits who fail the cut-off limit should nevertheless be referred for detailed neuropsychological evaluation.
Our study has certain limitations. First, because of its retrospective nature, it cannot be viewed as a validation study. Second, due to the lack of a gold standard for NPSLE diagnosis, it is not possible to calculate sensitivity and specificity values for the EULAR risk factors [30] . Third, the high concordance rates with the EULAR recommendations may be biased by the fact that both study centres are tertiary referral centres with experience in the management of patients with NPSLE. Last, some of the ACR case definitions were underrepresented or not represented at all in our cohort.
In summary, herein we report the first comparison between real-life clinical care of NPSLE patients and the evidence-based/expert consensus EULAR guidelines. Due to its non-specific and complex presentation, the management of NPSLE will continue to rely on multidisciplinary collaboration and experienced physician intuition. Nevertheless, for centres with less experience in SLE, the EULAR recommendations provide a useful, albeit imperfect, framework for the initial management of patients with neuropsychiatric involvement.
